Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20312464 | 0.77 | HSP90AA1 (0.31) | HSP90AA1 | |
| SCHEMBL708737 | 0.74 | LPL (0.44) | LPLLIPGP2RX7DGAT1 | |
| SCHEMBL29498702 | 0.74 | LPL (0.44) | LPLLIPGP2RX7DGAT1 | |
| SCHEMBL14478695 | 0.74 | LPL (0.41) | LPLLIPGDGAT1 | |
| SCHEMBL20312384 | 0.74 | HSP90AA1 (0.38) | HSP90AA1 | |
| SCHEMBL20312378 | 0.74 | HSP90AA1 (0.38) | HSP90AA1 | |
| SCHEMBL20312439 | 0.73 | HSP90AA1 (0.34) | HSP90AA1 | |
| SCHEMBL28771993 | 0.71 | LPL (0.35) | LPLLIPGF11P2RX7CA1 | |
| SCHEMBL321437 | 0.71 | LPL (0.53) | LPLLIPGF11CA1CA2 | |
| SCHEMBL15803151 | 0.71 | LPL (0.38) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118930554-A | Fused ring compound and application thereof | 西安瑞联新材料股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-110831926-B | Tetrahydronaphtyl urea derivatives | 持田制药株式会社 | 2023-11-21 | — | — | CN | disclosed |
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-07-16 | — | — | US | disclosed |
| US-10570167-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10504732-B2 | Impurity diffusion agent composition and method for manufacturing semiconductor substrate | TOKYO OHKA KOGYO CO, LTD. (JP) | 2019-12-10 | — | — | US | disclosed |
| EP-3558998-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2018-07-05 | — | — | US | disclosed |
| US-20180182624-A1 | IMPURITY DIFFUSION AGENT COMPOSITION AND METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2018-06-28 | — | — | US | disclosed |
| US-20180182624-A1 | IMPURITY DIFFUSION AGENT COMPOSITION AND METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2018-06-28 | — | — | US | disclosed |
| WO-2018119284-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | LPL 929/4885LIPG 777/4885HSP90AA1 3808/4885 |
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | LPL 929/4885LIPG 777/4885HSP90AA1 3808/4885 |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | LPL 929/4885LIPG 777/4885HSP90AA1 3808/4885 |
| US-20180182624-A1 | IMPURITY DIFFUSION AGENT COMPOSITION AND METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE | SLC43A1, SAMHD1, SNRPD2 | LPL 4045/4885LIPG 3869/4885HSP90AA1 877/4885 |
| US-10570167-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | LPL 929/4885LIPG 777/4885HSP90AA1 3808/4885 |
| US-10504732-B2 | Impurity diffusion agent composition and method for manufacturing semiconductor substrate | SLC43A1, SAMHD1, SNRPD2 | LPL 4045/4885LIPG 3869/4885HSP90AA1 877/4885 |
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | LPL 929/4885LIPG 777/4885HSP90AA1 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.